Ije Nwokori Acquires 118,516 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 118,516 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average price of GBX 72 per share, with a total value of £85,331.52.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 11th, Ije Nwokori purchased 202 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 74 per share, for a total transaction of £149.48.
• On Friday, June 12th, Ije Nwokori acquired 112,500 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 76 per share, with a total value of £85,500.
• On Wednesday, May 13th, Ije Nwokori bought 233 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 64 per share, for a total transaction of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The shares were sold at an average price of GBX 66, for a total value of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori purchased 232 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 65 per share, for a total transaction of £150.80.

Dr. Martens Price Performance

DOCS traded down GBX 0.90 during trading on Friday, hitting GBX 71.10. The company’s stock had a trading volume of 714,890 shares, compared to its average volume of 8,611,851. The firm has a market capitalization of £680.49 million, a price-to-earnings ratio of 29.62, a P/E/G ratio of 6.40 and a beta of 0.25. Dr. Martens plc has a twelve month low of GBX 59.15 and a twelve month high of GBX 100.87. The business’s fifty day simple moving average is GBX 68.37 and its 200 day simple moving average is GBX 69.35. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27.

Dr. Martens (LON:DOCS) last announced its earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The business had revenue of £764.90 million during the quarter. On average, equities research analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Berenberg Bank dropped their target price on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 100 price target on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.